ENVB Stock Price, Enveric Biosciences, . Quote, Chart

Market Summary

USD0.96+0.03

Market Closed

3.23%

ENVB Stock Price

View Fullscreen

ENVB RSI Chart

ENVB Valuation

Market Cap

7.0M

Price/Earnings (Trailing)

-0.4

Price/Sales (Trailing)

0.09

EV/EBITDA

-0.25

Price/Free Cashflow

-0.5

ENVB Price/Sales (Trailing)

ENVB Profitability

Operating Margin

20.66%

EBT Margin

-53.30%

Return on Equity

-883.88%

Return on Assets

-402.15%

Free Cashflow Yield

-201.36%

ENVB Fundamentals

ENVB Revenue

Revenue (TTM)

35.4M

ENVB Earnings

Earnings (TTM)

-17.3M

Earnings Growth (Yr)

60.41%

Earnings Growth (Qtr)

-21.75%

Breaking Down ENVB Revenue

Last 7 days

7.9%

Last 30 days

-4.9%

Last 90 days

10.3%

Trailing 12 Months

-50%

How does ENVB drawdown profile look like?

ENVB Financial Health

Current Ratio

1.53

ENVB Investor Care

Shares Dilution (1Y)

250.97%

Diluted EPS (TTM)

-10.7

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	38.8M	36.1M	35.4M	0
2019	42.6M	42.6M	41.1M	39.9M
2018	47.3M	46.1M	44.2M	43.0M
2017	41.5M	47.1M	49.5M	48.6M
2016	23.0M	25.7M	31.3M	36.1M
2015	16.8M	16.8M	16.9M	20.4M
2014	6.1M	11.5M	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Enveric Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 22, 2024	coveney kevin michael	acquired	-	-	60,000	chief financial officer
Feb 22, 2024	facchini peter j.	acquired	-	-	50,000	chief innovation officer
Feb 22, 2024	tucker joseph edward	acquired	-	-	100,000	chief executive officer
Sep 15, 2023	pasqualone frank	bought	2,140	2.14	1,000	-
Mar 13, 2023	coveney kevin michael	acquired	-	-	26,500	chief financial officer
Jan 25, 2023	facchini peter j.	acquired	-	-	17,000	chief innovation officer
Jan 25, 2023	tucker joseph edward	acquired	-	-	44,000	chief executive officer
Jan 25, 2023	hagel jillian marie	acquired	-	-	12,000	vice president of innovation
Jan 25, 2023	kanubaddi avani	acquired	-	-	10,000	president and coo
Oct 13, 2021	tucker joseph edward	acquired	-	-	16,374	chief executive officer

Which funds bought or sold ENVB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.02	-19,219	23,657	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	unchanged	-	-276	355	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-108	130	-%
Feb 13, 2024	ARMISTICE CAPITAL, LLC	new	-	354,900	354,900	-%
Feb 13, 2024	TORONTO DOMINION BANK	sold off	-100	-129	-	-%
Feb 13, 2024	ACADIAN ASSET MANAGEMENT LLC	reduced	-94.32	-10,000	-	-%
Feb 13, 2024	MORGAN STANLEY	unchanged	-	-1.00	1.00	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	added	31.73	-6,422	16,476	-%
Feb 13, 2024	AdvisorShares Investments LLC	reduced	-3.41	-154,801	184,383	0.04%

Are Funds Buying or Selling ENVB?

Are funds buying ENVB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ENVB

No. of Funds

Unveiling Enveric Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	273,109	SC 13G
Feb 06, 2024	intracoastal capital, llc	6.2%	145,000	SC 13G/A
Feb 05, 2024	hudson bay capital management lp	4.54%	110,357	SC 13G/A
Feb 14, 2023	advisorshares trust	5.60%	116,295	SC 13G
Feb 08, 2023	intracoastal capital, llc	9.4%	206,136	SC 13G/A
Feb 07, 2023	hudson bay capital management lp	5.04%	110,357	SC 13G
Feb 06, 2023	alpha capital anstalt	262%	47,028	SC 13G/A
Aug 01, 2022	intracoastal capital, llc	9.99%	129,842	SC 13G

Recent SEC filings of Enveric Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
May 03, 2024	424B5	Prospectus Filed
May 03, 2024	8-K	Current Report
Apr 16, 2024	ARS	ARS
Apr 16, 2024	DEF 14A	DEF 14A
Mar 28, 2024	8-K	Current Report
Mar 26, 2024	10-K	Annual Report
Mar 26, 2024	8-K	Current Report
Mar 19, 2024	8-K	Current Report
Mar 11, 2024	8-K	Current Report
Mar 11, 2024	424B5	Prospectus Filed

Peers (Alternatives to Enveric Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Enveric Biosciences, Inc. News

Latest updates

Enveric Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3
Revenue	2.8%	8,483	8,255	9,603	9,065	9,149	11,015	10,686	10,283	10,576	11,076	11,063	11,455	12,530	12,268	12,341	12,387	10,059	6,687	7,013	7,582	4,463
Cost Of Revenue	2.5%	6,596	6,437	7,721	7,335	7,249	8,633	8,546	8,377	8,230	8,687	8,720	9,414	9,966	9,935	9,040	12,053	8,362	5,170	1,900	4,254	3,023
Gross Profit	3.8%	1,887	1,818	1,882	1,729	1,899	2,382	2,140	1,906	2,346	2,389	2,343	2,040	2,563	2,333	3,301	2,263	1,697	1,517	1,256	3,328	1,440
Operating Expenses	-36.2%	490	768	837	3,714	3,464	3,859	3,438	12,706	-3,754	3,468	3,710	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-40.5%	427	717	837	-6,779	2,902	3,296	2,877	2,735	2,656	2,525	2,879	-	-	-	-	-	-	-	-	-	-
R&D Expenses	24.2%	63.00	51.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	-Infinity%	-0.10*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	48.4%	76.00	51.00	262	334	-252	157	143	146	190	183	211	187	-	-	-	-	-	-	-	-	-
Income Taxes	-259.3%	-27.86	17.00	22.00	404	-1.07	17.00	-31.21	6,324	25.00	-	-	-2,391	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	36.4%	-989	-1,555	-1,766	-2,128	40.00	-1,239	-1,891	-13,441	5,724	-1,260	-1,571	-3,416	-4,060	-3,263	-725	-2,443	-	-	-	-	-
EBT Margin	-Infinity%	-0.18*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	30.9%	-565	-818	-1,098	665	41.00	-1,256	-1,859	-19,765	5,699	-1,260	-1,571	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-Infinity%	-0.05*	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-35.0%	4,300	6,619	9,800	15,852	19,553	30,855	28,572	32,179	26,719	69,758	23,695	25,787	4,097	27,994	27,506	28,055	28,924	29,793	27,000	30,507	29,637
Current Assets	-38.5%	3,582	5,827	8,900	14,839	18,432	22,267	19,369	22,665	17,737	22,282	21,509	23,424	2,279	11,305	10,269	10,244	109	8,688	10,966	11,459	10,061
Cash Equivalents	-46.4%	2,288	4,267	7,081	12,562	17,724	21,201	18,009	21,695	17,356	21,448	20,618	22,657	1,578	2,840	2,088	1,267	44.00	1,601	1,601	1,723	114
Net PPE	-5.9%	507	539	595	639	677	713	783	777	294	141	-	-	-	91.00	105	116	83.00	65.00	60.00	58.00	59.00
Goodwill	-100.0%	-	253	295	337	380	1,468	1,562	1,611	1,588	9,062	-	-	-	13,730	13,730	13,730	13,730	13,730	13,730	13,730	13,730
Liabilities	-	-	-	-	-	3,996	7,254	5,968	7,737	4,413	14,391	4,876	6,795	10,806	14,818	14,627	17,839	1,920	18,932	13,753	19,345	18,878
Current Liabilities	-44.0%	2,344	4,184	4,926	4,438	3,996	2,598	2,325	2,094	2,737	2,163	1,168	627	681	13,993	12,769	17,099	1,920	14,482	13,522	14,705	14,689
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-19.7%	1,956	2,436	4,875	10,406	14,672	22,840	21,965	24,442	22,306	55,367	18,819	18,992	3,416	13,176	12,880	10,216	10,618	13,247	10,861	11,162	10,759
Retained Earnings	-3.7%	-96,499	-93,063	-90,241	-83,885	-79,207	-70,529	-68,050	-65,260	-60,736	-18,630	-15,918	-15,010	-11,759	-45,156	-44,085	-42,408	-4,894	-37,806	-37,872	-36,443	-34,478
Additional Paid-In Capital	5.0%	100,816	96,013	95,641	94,805	94,396	93,990	90,229	89,118	83,067	73,869	34,702	33,953	15,223	58,219	56,870	52,562	3,039	50,418	48,052	46,993	45,129
Accumulated Depreciation	-	358	-	-	-	179	-	-	-	-	2.00	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	25.5%	2,739	2,182	2,142	2,078	2,078	1,787	951	847	652	413	392	324	202	-	-	-	-	-	-	-	-
Float	-	-	-	7,100	-	-	-	11,000	-	-	-	51,000	-	-	-	7,046	-	-	-	15,760	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	36.1%	-1,751	-2,740	-4,465	-5,137	-3,462	-4,550	-4,585	-4,548	-4,067	-2,206	-2,021	-3,162	-2,249	-393	-351	-893	826	-	-490	-984	-1,002
Share Based Compensation	-2.2%	365	373	880	533	529	645	678	769	7,768	487	751	3,592	-	-	-	-	-	-	-	-	-
Cashflow From Investing	-290.0%	-38*	20*	17.00	-5.17	-6.19	-18.57	-53.89	-505	-189	3,055	-	-675	2.00	-6.17	3.00	-43.37	-56.63	-	-115	-111	18.00
Cashflow From Financing	-77.2%	-186	-105	-	-	-1*	7,824	958	9,398	7*	-9*	18.00	24,882	3,599	228	493	1,212	-1,371	-	484	1,448	293

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ENVB Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
General and administrative	$ 8,852,021	$ 11,605,761
Research and development	7,252,437	8,027,773
Impairment of intangible assets and goodwill		7,453,662
Depreciation and amortization	343,982	327,910
Total operating expenses	16,448,440	27,415,106
Loss from operations	(16,448,440)	(27,415,106)
Other (expense) income
Inducement expense, net	(1,848,235)
Change in fair value of warrant liabilities	94,396	4,315,236
Change in fair value of investment option liability	208,752	3,472,726
Change in fair value of derivative liability	727,000	(325,000)
Interest income (expense), net	3,708	(5,249)
Total other (expense) income	(814,379)	7,457,713
Net loss before income taxes	(17,262,819)	(19,957,393)
Income tax (expense) benefit	(28,913)	1,486,060
Net loss	(17,291,732)	(18,471,333)
Less preferred dividends attributable to non-controlling interest	19,041	33,014
Less deemed dividends attributable to accretion of embedded derivative at redemption value	147,988	295,976
Net loss attributable to shareholders	(17,458,761)	(18,800,323)
Other comprehensive loss
Foreign currency translation	(33,015)	(505,932)
Comprehensive loss	$ (17,491,776)	$ (19,306,255)
Net loss per share - basic	$ (8.09)	$ (13.00)
Net loss per share - diluted	$ (8.09)	$ (13.00)
Weighted average shares outstanding, basic	2,159,063	1,446,007
Weighted average shares outstanding, diluted	2,159,063	1,446,007

ENVB Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 2,287,977	$ 17,723,884
Prepaid expenses and other current assets	1,293,554	708,053
Total current assets	3,581,531	18,431,937
Other assets:
Property and equipment, net	507,377	677,485
Right-of-use operating lease asset		63,817
Intangible assets, net	210,932	379,686
Total other assets	718,309	1,120,988
Total assets	4,299,840	19,552,925
Current liabilities:
Accounts payable	1,218,783	463,275
Accrued liabilities	1,075,643	1,705,655
Current portion of right-of-use operating lease obligation		63,820
Investment option liability	23,608	851,008
Warrant liability	25,470	185,215
Derivative liability		727,000
Total current liabilities	2,343,504	3,995,973
Commitments and contingencies (Note 10)
Mezzanine equity
Series C redeemable preferred stock, $0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of December 31, 2023 and 2022, respectively
Redeemable non-controlling interest		885,028
Total mezzanine equity		885,028
Shareholders’ equity
Preferred stock, $0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $0.01 par value, 3,600,000 shares authorized, 0 shares issued and outstanding as of December 31, 2023 and 2022, respectively
Common stock, $0.01 par value, 100,000,000 shares authorized, 2,739,315 and 2,078,271 shares issued and outstanding as of December 31, 2023 and 2022, respectively	27,392	20,782
Additional paid-in capital	100,815,851	94,395,662
Stock subscription receivable	(1,817,640)
Accumulated deficit	(96,499,518)	(79,207,786)
Accumulated other comprehensive loss	(569,749)	(536,734)
Total shareholders’ equity	1,956,336	14,671,924
Total liabilities, mezzanine equity, and shareholders’ equity	$ 4,299,840	$ 19,552,925

About Enveric Biosciences, Inc.

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

CEO	Dr. Joseph Edward Tucker Ph.D.
WEBSITE	enveric.com
INDUSTRY	Biotechnology
EMPLOYEES	25

Enveric Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Enveric Biosciences, Inc.? What does ENVB stand for in stocks?

ENVB is the stock ticker symbol of Enveric Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Enveric Biosciences, Inc. (ENVB)?

As of Fri May 03 2024, market cap of Enveric Biosciences, Inc. is 7 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENVB stock?

You can check ENVB's fair value in chart for subscribers.

What is the fair value of ENVB stock?

You can check ENVB's fair value in chart for subscribers. The fair value of Enveric Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Enveric Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ENVB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Enveric Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether ENVB is over valued or under valued. Whether Enveric Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Enveric Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENVB.

What is Enveric Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, ENVB's PE ratio (Price to Earnings) is -0.4 and Price to Sales (PS) ratio is 0.09. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENVB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Enveric Biosciences, Inc.'s stock?

In the past 10 years, Enveric Biosciences, Inc. has provided -0.427 (multiply by 100 for percentage) rate of return.